Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.
about
H+/K+-ATPase inhibitors: a patent review.A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapyProton pump inhibitor for non-erosive reflux disease: a meta-analysis.Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safetyEsomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritisEfficacy of esomeprazole in treating acid-related diseases in Japanese populationsReview article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.A review of rabeprazole in the treatment of acid-related diseasesProton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?Asia-Pacific consensus on the management of gastroesophageal reflux disease: update.A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD).Proton pump inhibitors: an update of their clinical use and pharmacokinetics.Esomeprazole: a proton pump inhibitor.Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.The pharmacology of esomeprazole and its role in gastric acid related diseases.Meta-analysis used to identify factors associated with the effectiveness of proton pump inhibitors against non-erosive reflux disease.Guidelines for the diagnosis and management of gastroesophageal reflux disease: an evidence-based consensus.Pretreatment prediction of symptom response to proton pump inhibitor therapy.One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis.Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial.Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study.Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease.Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.Frequency scale symptoms for gastroesophageal reflux disease (Frequency Scale for Symptoms of GERD) predicts need for addition of prokinetics to proton pump inhibitor therapy.It is possible to classify non-erosive reflux disease (NERD) patients into endoscopically normal groups and minimal change groups by subjective symptoms and responsiveness to rabeprazole -- a report from a study with Japanese patients.Rabeprazole: a pharmacologic and clinical review for acid-related disorders
P2860
Q34315036-81FC1C3C-7A95-4719-B137-729B67344FBFQ34647904-4D761D2E-D77E-48FD-A930-9273DEEF6C19Q34831226-4E5D7808-5055-4EC0-A447-4FFA5D5A6630Q35074278-81FA5030-5C78-454D-93C7-A8D8C84B74E5Q35167717-6159F912-444A-42BE-846E-334803A83A8FQ35716289-7CC9B5DF-C80B-414F-8B25-8A038054879AQ35987201-AF9F4639-6F02-4354-90F4-9CB7C05FD200Q36398683-A2CF83D2-5FC4-4022-B3ED-3CE2BB9DBF50Q36661321-A59A835F-A47A-4670-A0AF-8D6EE622075BQ37030772-CD6F343B-7724-4C5D-A4A3-DD7EBE5B9581Q37048727-19E06762-B479-426B-B331-D11C9AB5F3B4Q37160360-2771A019-8D8B-481F-A832-0EFFCC4D8A69Q37235086-84D04ADF-9E7B-42B0-8FD6-DB87E83E2864Q37390644-DB6E1E31-746B-4E92-847A-05F2E752413BQ37543446-5F0F8C99-6437-4751-BF24-6AABAE5682D0Q37552951-DE34969B-3B1D-43B4-B9C0-FC00984C3CF6Q37585533-CC61BFC0-A142-4F62-87F8-A5478E2FDB46Q37762466-00A4A784-195A-4D58-BE9A-FD8C4451CBCDQ39023140-549C9232-BAF1-45CB-8CCE-536168A9E57FQ39115202-B126385A-991B-4CC6-9300-219912644EA2Q39252347-A83AD894-59CB-4B66-A4E1-67F35C5842C4Q39266717-20239CFC-3DE3-484B-8ABE-3CA500650010Q39276657-D39B0DD3-01C7-4AB8-BA01-20B397F59364Q39307670-DEEF1989-DCF0-4BA5-B94B-684464B03718Q39334427-2C4408E6-2054-454E-A677-B7FE023104A7Q39420822-1FC3B8AA-5107-4A2C-ABB1-E4A519531DA1Q42689388-80918D9A-2817-4820-A96D-76FE65716755Q44600156-589A0981-0C26-47F9-BFD7-CEE5FA6F076CQ46037784-75225A05-2603-4570-95FA-5DA097706FEBQ46203790-703C5CA0-3D2C-4FC6-A117-C0A1927A4DB0Q46432261-F4E8CC98-340F-4FF5-A7F4-DADE7D7C91CDQ46605924-0EE2B962-9274-4304-96A3-DC5C2A474817Q56431955-DAB9E6F3-34B8-4D79-B2BD-4E1DDE15621A
P2860
Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Rabeprazole vs esomeprazole in ...... ble-blind study in urban Asia.
@ast
Rabeprazole vs esomeprazole in ...... ble-blind study in urban Asia.
@en
type
label
Rabeprazole vs esomeprazole in ...... ble-blind study in urban Asia.
@ast
Rabeprazole vs esomeprazole in ...... ble-blind study in urban Asia.
@en
prefLabel
Rabeprazole vs esomeprazole in ...... ble-blind study in urban Asia.
@ast
Rabeprazole vs esomeprazole in ...... ble-blind study in urban Asia.
@en
P2093
P2860
P356
P1476
Rabeprazole vs esomeprazole in ...... uble-blind study in urban Asia
@en
P2093
P2860
P304
P356
10.3748/WJG.V11.I20.3091
P407
P577
2005-05-01T00:00:00Z